R
Ronald B. Goldberg
Researcher at University of Miami
Publications - 31
Citations - 4132
Ronald B. Goldberg is an academic researcher from University of Miami. The author has contributed to research in topics: Diabetes mellitus & Metformin. The author has an hindex of 22, co-authored 31 publications receiving 3807 citations. Previous affiliations of Ronald B. Goldberg include George Washington University & University of Chicago.
Papers
More filters
Journal ArticleDOI
The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial.
Trevor J. Orchard,Marinella Temprosa,Ronald B. Goldberg,Steven M. Haffner,Robert E. Ratner,Santica Marcovina,Sarah E. Fowler +6 more
TL;DR: In this paper, the authors used lifestyle intervention and metformin therapy to reduce the incidence of metabolic syndrome in the participants of the Diabetes Prevention Program. But, only half of the participants had the metabolic syndrome.
Journal ArticleDOI
The Diabetes Prevention Program: Design and methods for a clinical trial in the prevention of type 2 diabetes
George A. Bray,K. S. Polonsky,Pamela G. Watson,Ronald B. Goldberg,Steven M. Haffner,Richard F. Hamman,Edward S. Horton,S. F. Kahn,A. E. Kitabchi,Boyd E. Metzger,David M. Nathan,J. M. Olefsky,F. X. Pi-Sunyer,Melvin Prince,Robert E. Ratner,M. F. Saad,S. Dagogo Jack,C. D. Saudek,David Schade,H. Shamoon,Rena R. Wing,R. F. Arakaki,W. C. Krowler,R P Bain,Santica Marcovina,P. M. Rautaharju,Elizabeth J. Mayer-Davis,D. H. O'Leary,E. R. Stamm +28 more
TL;DR: The Diabetes Prevention Program is a randomized clinical trial testing strategies to prevent or delay the development of type 2 diabetes in high-risk individuals with elevated fasting plasma glucose concentrations and impaired glucose tolerance.
Journal ArticleDOI
Long-term Effects of Lifestyle Intervention or Metformin on Diabetes Development and Microvascular Complications: the DPP Outcomes Study
David M. Nathan,Elizabeth Barrett-Connor,Jill P. Crandall,S. L. Edelstein,Ronald B. Goldberg,Edward S. Horton,W. C. Knowler,Kieren J. Mather,Trevor J. Orchard,Xavier Pi-Sunyer,David Schade,M. Temprosa +11 more
TL;DR: Lifestyle intervention or metformin significantly reduce diabetes development over 15 years, and those who did not progress to diabetes had a lower prevalence of microvascular complications than those who progressed.
Journal ArticleDOI
Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program.
Robert E. Ratner,Ronald B. Goldberg,Steven M. Haffner,Santica Marcovina,Trevor J. Orchard,Sarah E. Fowler,Marinella Temprosa +6 more
TL;DR: Lifestyle intervention improves CVD risk factor status compared with placebo and metformin therapy and achieved risk factor modifications suggest that longer intervention may reduce CVD event rates.
Journal ArticleDOI
The diabetes prevention program: Baseline characteristics of the randomized cohort
George A. Bray,I. W. Culbert,C. M. Champagne,L. Dawson,B. Eberhardt,F. L. Greenway,F. G. Guillory,A. A. Hebert,M. L. Jeffirs,B. M. Kennedy,Jennifer C. Lovejoy,L. E. Melancon,L. H. Morris,J. Perault,Donna H. Ryan,D. A. Sanford,K. G. Smith,L. L. Smith,J. A. St. Amant,E. Tucker,R. T. Tulley,P. C. Vicknair,D. Williamson,J. J. Zachwieja,J. A. Tobian,Margaret J. Matulik,B. Clarke,D. A. Collins,K. B. Czech,C. DeSandre,David A. Ehrmann,G. Geiger,B. Harding-Clay,R. M. Hilbrich,W. L. McNabb,K. S. Polonsky,A. R. Semenske,K. A. Stepp,Pamela G. Watson,J. T. Mendoza,K. A. Smith,B. J. Goldstein,C. Lark,R. Liberoni,L. Murphy,C. Pepe,John Spandorfer,Ronald B. Goldberg,P. Rowe,J. Calles,P. Casanova,R. P. Donahue,H. J. Florez,A. Giannella,V. McLymont,J. Mendez,P. O'Hara,J. Ojito,R. Prineas,Steven M. Haffner,Maria G. Montez,H. Miettinen,C. M. Mobley,L. A. Mykkanen,M. M. Rozek,Richard F. Hamman,P. V. Nash,B. N. Calonge,James O. Hill,S. R. Hoyer,B. T. Jortberg,M. Miller-Stone,Judith G. Regensteiner,H. Seagle,S. C. Steinke,L. Testaverde,B. Van-Dorsten,Edward S. Horton,K. E. Lawton,R. A. Arky,M. Bryant,J. P. Burke,E. Caballero,K. M. Callaghan,O. P. Ganda,T. Franklin,S. D. Jackson,A. M. Jacobsen,L. M. Kula,M. Kocal,M. A. Malloy,M. Nicosia,C. F. Oldmixon,J. Pan,M. Quitingon,S. Rubtchinsky,E. W. Seely,D. Schweizer +97 more
TL;DR: The DPP has successfully randomized a large cohort of participants with a wide distribution of age, obesity, and ethnic and racial backgrounds who are at high risk for developing type 2 diabetes.